MS05-P13 VHHs As Tools In Antibody Assisted Structure Based Drug Discovery SURA ABBOOD (Molecular and Cell Biology/ Leicester university , Leicester, United Kingdom)email: sma43@leicester.ac.ukCytokines such as interleukin-6 (IL6) are attractive therapeutic targets in inflammatory diseases. Interleukin-6 is a secreted cytokine, produced by different cell types, but it originates mainly from macrophages and monocytes at the site of inflammation [1]. IL6 is a multifunctional cytokine and mediates its biological function via a hexameric signaling complex composed of two molecules each of IL6, gp80 and gp130 [2]. It is a key player in immunological response and has been implicated in the pathogenesis of a wide range of inflammatory diseases such as rheumatoid arthritis [3]. Heavy chain only antibodies are produced by the immune system of a limited number of animals, including camels and llamas and due to their small size are an attractive tool for antibody based drug discovery. A number of antigen-binding domain (VHH) antibodies that target IL6 have developed to inhibit the hexameric signaling complex formation. VHH94 was derived from a camel heavy chain antibody isolated after immunization with a interleukin-6-gp80 fusion protein. VHH94 was found to enhance the binding of IL-6 to gp80 potentially through binding to an allosteric site on IL-6 and partially inhibited the signaling of IL6. The combination of X-ray crystallography and NMR spectroscopy are using to provide a clear overall picture of the IL6-VHH94 interaction site. 
 
References:

1. GABAY, C. (2006). Arthritis Research and Therapy, 8, Suppl 2:S3.

2. Boulanger, M. J. et al (2003). Science, 300, 2101–2104.

3. McInnes, I. B. & Schett, G. (2007). Nat. Rev. Immunol., 7, 429 – 442.

Keywords: IL-6, VHH94, Structure